Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Official title: BCCMA: Overcoming chemoresistance in ovarian cancer: Identification and validation of biomarkers and targetable drivers of platinum resistance
Funded at VA Greater Los Angeles Healthcare System · NIH-11498011 · Data updated 2026-11-12
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| NIH project number | 5I01BX006020-04 |
| Project ID | NIH-11498011 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with high-grade serous ovarian carcinoma or platinum-resistant ovarian cancer who are able to provide tissue samples and related clinical data.
✕Less likely to help
Patients without platinum resistance or access to trialed therapies may see no direct benefit.
What this research studies
This grant supports three interconnected projects using patient-derived data and tissue analyses to understand why high-grade serous ovarian cancer stops responding to platinum chemotherapy. By applying digital spatial profiling and systems biology, the team aims to identify biomarkers and potential targets that predict or drive resistance. The work seeks to translate findings into strategies that could guide personalized treatment and improve survival for people with this cancer. Patients may contribute tissue samples and clinical information to help map the resistance landscape.
Why it matters
Potential benefit: If successful, the research could lead to tests that predict resistance and new treatment options that overcome it for ovarian cancer patients.
How similar studies have gone: Similar approaches have identified biomarkers and helped guide targeted strategies in ovarian cancer, supporting potential impact of this work.
Where this research is happening
-
VA Greater Los Angeles Healthcare System
Los Angeles, United States Active
Researchers
- Principal investigator: Orsulic, Sandra — VA Greater Los Angeles Healthcare System
- Study coordinator: Orsulic, Sandra
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Tumor-Niche Co-evolution in Ovarian Cancer Metastasis and Resistance
This research explores how ovarian cancer cells interact with their surrounding tissue to understand how metastasis and resistance to therapy develop, with potential to guide better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.